Skip to main content

Advertisement

Figure 1 | Breast Cancer Research

Figure 1

From: QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

Figure 1

Breast cancer cells exhibit dose-dependent decrease in (a) cell viability and (b) P-AKT in response to increasing concentrations of the ILK small molecule inhibitor, QLT0267. (a) Seven breast cancer cell lines (LCC6, LCC6Her2, SKBR-3, KPL-4, BT-474, MBA-MB-468, and MCF-7) were treated with increasing doses (1 μm to 256 μM) of 267 for 72 hours and cell viability was evaluated using the AlamarBlue® assay. Percentage cell viability relative to control (untreated) cells are shown. Each data point represents the mean (± standard deviation) determined from three experiments done in triplicate. Treated cells were assessed for phosphorylated protein kinase B (P-AKT) using western blot analysis of protein lysates collected eight hours after treatment. (b) Western blot were analyzed using densitometry, dose-response curves were generated and analyzed using Calcusyn to determine the ED50 of 267 for PAKT suppression for each cell line. 267 = QLT0267; ILK = integrin-linked kinase.

Back to article page